Weil Advises MPI Research in its $800M Sale to Charles River Laboratories International, Inc.

Print Print

Weil is advising MPI Research (a portfolio company of Avista Capital Partners), a non-clinical contract research organization (CRO) providing comprehensive testing services to biopharmaceutical and medical device companies worldwide, in its pending $800 million sale to Charles River Laboratories International, Inc. The transaction is expected to close during the second quarter of 2018, subject to customary regulatory approvals and customary closing conditions.

The Weil team advising MPI Research is led by Private Equity partner Peter Feist and includes Corporate Chairman and Mergers & Acquisitions partner Michael Aiello; private equity associates Philip Wolf, Ololade Oladapo (Not Yet Admitted in New York) and Larissa Lucas (Not Yet Admitted in New York); Banking & Finance partner Andrew Yoon; Capital Markets partner Heather Emmel; Technology & IP Transactions head Michael Epstein; Tax partner Helyn Goldstein; Executive Compensation & Benefits partner Amy Rubin; Real Estate partner Samuel Zylberberg; Environmental head Annemargaret Connolly; Employment Litigation partner Gary Friedman; Antitrust partner John Scribner; White Collar Defense, Regulatory and Investigations co-head Steven Tyrell; White Collar Defense, Regulatory and Investigations partner Holly Loiseau; International Arbitration & Trade partner Ted Posner; Litigation partner Holly Loiseau; Environmental counsel Thomas Goslin and John O’Loughlin; Antitrust counsel Michael Naughton; Banking & Finance associates Steven LePorin and Sean McClay; Technology & IP Transactions associates Dennis Adams and Rami Sherman (Not Yet Admitted in New York); Tax associate Liam Murphy; Executive Compensation & Benefits associates Jennifer Britz and Daniel Rios (Not Yet Admitted in New York); Real Estate associate Joshua Rudin; Employment Litigation associate Thomas McCarthy; Insurance associate Gabriel Gershowitz; Antitrust associate Jonathan Goldsmith; White Collar Defense, Regulatory and Investigations associate Timothy Welch; and Litigation associate Nicole Prunetti.